Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.28 | 1.06 | 0.87 | -1.79 |
| FCF Yield | -0.85% | -1.81% | -5.44% | -6.11% |
| EV / EBITDA | -71.31 | -42.41 | -18.44 | -14.68 |
| Quality | ||||
| ROIC | -10.08% | -26.32% | -38.73% | -64.45% |
| Gross Margin | 91.63% | 92.73% | 91.79% | 90.17% |
| Cash Conversion Ratio | 0.98 | 0.89 | 1.05 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 39.81% | 78.46% | 122.78% | 1,004.67% |
| Free Cash Flow Growth | 40.95% | 54.06% | -4.27% | -12.82% |
| Safety | ||||
| Net Debt / EBITDA | 2.48 | 0.82 | 0.49 | 0.23 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.17 | 2.90 | 0.85 | 1.01 |
| Cash Conversion Cycle | 90.60 | 91.73 | 351.64 | 56.29 |